These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 16858980)

  • 1. Dengue vaccine.
    Simasathien S; Watanaveeradej V
    J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S363-77. PubMed ID: 16858980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of dengue virus and the development of a vaccine.
    Murrell S; Wu SC; Butler M
    Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Future prospects in developing of dengue vaccines].
    Valero N; Levy A
    Invest Clin; 2008 Jun; 49(2):135-8. PubMed ID: 18717261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges for the formulation of a universal vaccine against dengue.
    Chokephaibulkit K; Perng GC
    Exp Biol Med (Maywood); 2013 May; 238(5):566-78. PubMed ID: 23856907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.
    Koraka P; Benton S; van Amerongen G; Stittelaar KJ; Osterhaus AD
    Vaccine; 2007 Jul; 25(29):5409-16. PubMed ID: 17560694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
    Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chambonneau L; Saluzzo JF; Bhamarapravati N
    Pediatr Infect Dis J; 2004 Feb; 23(2):99-109. PubMed ID: 14872173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
    Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
    J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances in the development of a vaccine against dengue].
    Guzmán MG
    Acta Cient Venez; 1998; 49 Suppl 1():38-45. PubMed ID: 10030053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flaviviruses and flavivirus vaccines.
    Heinz FX; Stiasny K
    Vaccine; 2012 Jun; 30(29):4301-6. PubMed ID: 22682286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
    Guy B; Nougarede N; Begue S; Sanchez V; Souag N; Carre M; Chambonneau L; Morrisson DN; Shaw D; Qiao M; Dumas R; Lang J; Forrat R
    Vaccine; 2008 Oct; 26(45):5712-21. PubMed ID: 18762226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
    Kitchener S; Nissen M; Nasveld P; Forrat R; Yoksan S; Lang J; Saluzzo JF
    Vaccine; 2006 Feb; 24(9):1238-41. PubMed ID: 16213632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue virus vaccine development.
    Yauch LE; Shresta S
    Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding dengue pathogenesis: implications for vaccine design.
    Stephenson JR
    Bull World Health Organ; 2005 Apr; 83(4):308-14. PubMed ID: 15868023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dengue vaccines approach the finish line.
    Edelman R
    Clin Infect Dis; 2007 Jul; 45 Suppl 1():S56-60. PubMed ID: 17582571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of interferences between dengue vaccine serotypes in a monkey model.
    Guy B; Barban V; Mantel N; Aguirre M; Gulia S; Pontvianne J; Jourdier TM; Ramirez L; Gregoire V; Charnay C; Burdin N; Dumas R; Lang J
    Am J Trop Med Hyg; 2009 Feb; 80(2):302-11. PubMed ID: 19190230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dengue vaccines: challenges, development, current status and prospects.
    Ghosh A; Dar L
    Indian J Med Microbiol; 2015; 33(1):3-15. PubMed ID: 25559995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.
    Guy B; Chanthavanich P; Gimenez S; Sirivichayakul C; Sabchareon A; Begue S; Yoksan S; Luxemburger C; Lang J
    Vaccine; 2004 Sep; 22(27-28):3563-74. PubMed ID: 15315835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.